FY2024 Earnings Forecast for RVPH Issued By Zacks Small Cap

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Stock analysts at Zacks Small Cap upped their FY2024 earnings per share (EPS) estimates for shares of Reviva Pharmaceuticals in a report released on Monday, December 23rd. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings of ($0.97) per share for the year, up from their previous estimate of ($0.98). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($1.01) per share. Zacks Small Cap also issued estimates for Reviva Pharmaceuticals’ Q4 2024 earnings at ($0.22) EPS.

Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd.

Reviva Pharmaceuticals Stock Up 8.5 %

NASDAQ RVPH opened at $1.78 on Wednesday. Reviva Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $5.67. The firm has a market capitalization of $59.52 million, a price-to-earnings ratio of -1.60 and a beta of -0.02. The company has a fifty day moving average of $1.39 and a two-hundred day moving average of $1.24.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its stake in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the quarter. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.